| (3S,5R)-fluvastatin | multiple interactions | ISO | RGD:734299 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA | CTD | PMID:16996129 |
| 17beta-estradiol | affects expression | ISO | RGD:734299 | 6480464 | Estradiol affects the expression of BCL2L11 mRNA | CTD | PMID:21826169 |
| 17beta-estradiol | increases expression | ISO | RGD:734299 | 6480464 | Estradiol results in increased expression of BCL2L11 mRNA | CTD | PMID:23373633 |
| 1H-pyrazole | increases expression | ISO | RGD:734300 | 6480464 | pyrazole results in increased expression of BCL2L11 mRNA | CTD | PMID:17945193 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | RGD:734300 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA] | CTD | PMID:21851831 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:734300 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA | CTD | PMID:15800033 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:734300 | 6480464 | Tetrachlorodibenzodioxin affects the expression of BCL2L11 mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:734300 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA] | CTD | PMID:21851831 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:734300 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA | CTD | PMID:15800033 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:734300 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2L11 mRNA | CTD | PMID:19770486 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA | CTD | PMID:19520675 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | ISO | RGD:734300 | 6480464 | D-JNKI-1 inhibits the reaction [[Trinitrobenzenesulfonic Acid results in increased expression of MAPK9 protein] promotes the reaction [BCL2L11 protein binds to MAPK9 protein]]; more ... | CTD | PMID:22427801 |
| 2,4,6-trinitrobenzenesulfonic acid | increases expression | ISO | RGD:734300 | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of BCL2L11 protein | CTD | PMID:22427801 |
| 2-butoxyethanol | increases expression | ISO | RGD:734300 | 6480464 | n-butoxyethanol results in increased expression of BCL2L11 mRNA | CTD | PMID:19812364 |
| 2-methoxyethanol | increases expression | EXP | | 6480464 | methyl cellosolve results in increased expression of BCL2L11 mRNA | CTD | PMID:19643169 |
| 4-hydroxynon-2-enal | increases expression | ISO | RGD:734300 | 6480464 | 4-hydroxy-2-nonenal results in increased expression of BCL2L11 mRNA | CTD | PMID:19191707 |
| 4-vinylcyclohexene dioxide | affects expression | ISO | RGD:734300 | 6480464 | 4-vinyl-1-cyclohexene dioxide affects the expression of BCL2L11 mRNA | CTD | PMID:20829426 |
| 5-aza-2'-deoxycytidine | decreases methylation | ISO | RGD:734299 | 6480464 | decitabine results in decreased methylation of BCL2L11 promoter | CTD | PMID:19403302 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:734299 | 6480464 | decitabine results in increased expression of BCL2L11 mRNA; more ... | CTD | PMID:19403302 |
| 7-ketocholesterol | affects localization | ISO | RGD:734299 | 6480464 | 7-ketocholesterol affects the localization of BCL2L11 protein | CTD | PMID:15955068 |
| 8-bromo-3',5'-cyclic AMP | multiple interactions | ISO | RGD:734299 | 6480464 | [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein | CTD | PMID:16709600 |
| 9-cis-retinoic acid | multiple interactions | ISO | RGD:734299 | 6480464 | seocalcitol inhibits the reaction [alitretinoin results in increased expression of BCL2L11 protein] | CTD | PMID:16340750 |
| 9-cis-retinoic acid | increases expression | ISO | RGD:734299 | 6480464 | alitretinoin results in increased expression of BCL2L11 protein | CTD | PMID:16340750 |
| acetylsalicylic acid | increases expression | ISO | RGD:734299 | 6480464 | Aspirin results in increased expression of BCL2L11 mRNA | CTD | PMID:19936928 |
| actinomycin D | multiple interactions | ISO | RGD:734300 | 6480464 | Dactinomycin inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 mRNA] | CTD | PMID:16166651 |
| aflatoxin B1 | increases expression | ISO | RGD:734300 | 6480464 | Aflatoxin B1 results in increased expression of BCL2L11 mRNA | CTD | PMID:19770486 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:734299 | 6480464 | Tretinoin results in decreased expression of BCL2L11 protein | CTD | PMID:19176369 |
| amiodarone | increases expression | ISO | RGD:734299 | 6480464 | Amiodarone results in increased expression of BCL2L11 mRNA | CTD | PMID:19774075 |
| ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of BCL2L11 mRNA | CTD | PMID:16483693 |
| benzo[a]pyrene | increases expression | ISO | RGD:734299 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | CTD | PMID:15735009 |
| benzo[a]pyrene | increases expression | ISO | RGD:734300 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | CTD | PMID:19770486 PMID:21715664 |
| benzo[a]pyrene | increases expression | ISO | RGD:734300 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | CTD | PMID:21715664 PMID:19770486 |
| benzo[a]pyrene | decreases expression | ISO | RGD:734300 | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2L11 mRNA | CTD | PMID:20713471 |
| benzo[a]pyrene | increases expression | ISO | RGD:734300 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | CTD | PMID:21715664 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:734300 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in increased expression of BCL2L11 mRNA | CTD | PMID:21715664 |
| benzo[b]fluoranthene | increases expression | ISO | RGD:734300 | 6480464 | benzo(b)fluoranthene results in increased expression of BCL2L11 protein | CTD | PMID:21392559 |
| bis(2-chloroethyl) sulfide | increases expression | ISO | RGD:734300 | 6480464 | Mustard Gas results in increased expression of BCL2L11 mRNA | CTD | PMID:18955075 |
| bisphenol A | affects expression | ISO | RGD:734299 | 6480464 | bisphenol A affects the expression of BCL2L11 mRNA | CTD | PMID:21826169 |
| bisphenol A | increases methylation | ISO | RGD:734299 | 6480464 | bisphenol A results in increased methylation of BCL2L11 gene | CTD | PMID:22576693 |
| bisphenol A | decreases expression | ISO | RGD:734299 | 6480464 | bisphenol A results in decreased expression of BCL2L11 mRNA | CTD | PMID:22576693 |
| cadmium dichloride | increases expression | ISO | RGD:734299 | 6480464 | Cadmium Chloride results in increased expression of BCL2L11 | CTD | PMID:21787858 |
| calcitriol | decreases expression | ISO | RGD:734299 | 6480464 | Calcitriol results in decreased expression of BCL2L11 mRNA | CTD | PMID:12071473 |
| chromium(6+) | increases expression | ISO | RGD:734299 | 6480464 | chromium hexavalent ion results in increased expression of BCL2L11 mRNA | CTD | PMID:17382205 |
| cisplatin | multiple interactions | ISO | RGD:734299 | 6480464 | Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA]; more ... | CTD | PMID:21092744 |
| cisplatin | increases expression | ISO | RGD:734299 | 6480464 | Cisplatin results in increased expression of BCL2L11 mRNA | CTD | PMID:21092744 |
| clofibrate | multiple interactions | ISO | RGD:734300 | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA; more ... | CTD | PMID:17585979 |
| cocaine | increases expression | EXP | | 6480464 | Cocaine results in increased expression of BCL2L11 mRNA | CTD | PMID:16076954 |
| copper atom | multiple interactions | EXP | | 6480464 | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein; more ... | CTD | PMID:22276220 |
| copper(0) | multiple interactions | EXP | | 6480464 | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein; more ... | CTD | PMID:22276220 |
| crocidolite asbestos | decreases expression | ISO | RGD:734299 | 6480464 | Asbestos, Crocidolite results in decreased expression of BCL2L11 mRNA | CTD | PMID:18687144 |
| curcumin | increases expression | ISO | RGD:734299 | 6480464 | Curcumin results in increased expression of BCL2L11 mRNA | CTD | PMID:17332930 |
| dexamethasone | increases response to substance | ISO | RGD:734299 | 6480464 | BCL2L11 protein results in increased susceptibility to Dexamethasone | CTD | PMID:14996839 |
| dexamethasone | increases response to substance | ISO | RGD:734300 | 6480464 | BCL2L11 protein results in increased susceptibility to Dexamethasone | CTD | PMID:14996839 |
| dexamethasone | increases expression | ISO | RGD:734300 | 6480464 | Dexamethasone results in increased expression of BCL2L11 mRNA alternative form | CTD | PMID:17953376 |
| dexamethasone | increases expression | ISO | RGD:734300 | 6480464 | Dexamethasone results in increased expression of BCL2L11 protein | CTD | PMID:14996839 |
| dexamethasone | multiple interactions | ISO | RGD:734299 | 6480464 | NR3C1 protein affects the reaction [Dexamethasone results in increased expression of BCL2L11 protein] | CTD | PMID:18515658 |
| dexamethasone | multiple interactions | ISO | RGD:734299 | 6480464 | GSTM1 protein inhibits the reaction [Dexamethasone results in increased phosphorylation of BCL2L11 protein] | CTD | PMID:20067466 |
| dexamethasone | increases phosphorylation | ISO | RGD:734299 | 6480464 | Dexamethasone results in increased phosphorylation of BCL2L11 protein | CTD | PMID:20067466 |
| dexamethasone | increases expression | ISO | RGD:734299 | 6480464 | Dexamethasone results in increased expression of BCL2L11 mRNA | CTD | PMID:12782123 |
| diarsenic trioxide | increases expression | ISO | RGD:734299 | 6480464 | arsenic trioxide results in increased expression of BCL2L11 mRNA | CTD | PMID:17530438 |
| diarsenic trioxide | increases expression | ISO | RGD:734299 | 6480464 | arsenic trioxide results in increased expression of BCL2L11 protein | CTD | PMID:21655183 PMID:17203211 |
| diarsenic trioxide | increases expression | ISO | RGD:734299 | 6480464 | arsenic trioxide results in increased expression of BCL2L11 protein | CTD | PMID:17203211 PMID:21655183 |
| diarsenic trioxide | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 mutant form inhibits the reaction [arsenic trioxide results in increased cleavage of CASP3 protein]; more ... | CTD | PMID:21655183 |
| diazoxide | increases expression | ISO | RGD:734300 | 6480464 | Isoproterenol results in increased expression of BCL2L11 protein | CTD | PMID:14996839 |
| dibutyl phthalate | decreases expression | ISO | RGD:734300 | 6480464 | Dibutyl Phthalate results in decreased expression of BCL2L11 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | decreases expression | ISO | RGD:734300 | 6480464 | Dibutyl Phthalate results in decreased expression of BCL2L11 mRNA | CTD | PMID:17361019 PMID:21266533 |
| docetaxel anhydrous | multiple interactions | ISO | RGD:734299 | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein]; more ... | CTD | PMID:17317842 |
| docetaxel anhydrous | increases degradation | ISO | RGD:734299 | 6480464 | docetaxel results in increased degradation of BCL2L11 protein | CTD | PMID:17317842 |
| doxorubicin | multiple interactions | ISO | RGD:734299 | 6480464 | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein; more ... | CTD | PMID:20856197 |
| doxorubicin | decreases expression | ISO | RGD:734299 | 6480464 | Doxorubicin results in decreased expression of BCL2L11 protein | CTD | PMID:17339365 |
| doxorubicin | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium]; more ... | CTD | PMID:17339365 |
| elemental selenium | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium]; more ... | CTD | PMID:17339365 |
| elemental selenium | increases expression | ISO | RGD:734299 | 6480464 | Selenium results in increased expression of BCL2L11 protein | CTD | PMID:17339365 |
| flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of BCL2L11 protein | CTD | PMID:20850791 |
| folic acid | affects expression | ISO | RGD:734299 | 6480464 | Folic Acid affects the expression of BCL2L11 mRNA | CTD | PMID:16361273 |
| furan | increases expression | EXP | | 6480464 | furan results in increased expression of BCL2L11 mRNA | CTD | PMID:20562052 |
| furan | increases expression | EXP | | 6480464 | furan results in increased expression of BCL2L11 mRNA | CTD | PMID:20562052 PMID:22079235 |
| furosemide | affects expression | EXP | | 6480464 | Furosemide affects the expression of BCL2L11 mRNA | CTD | PMID:17497460 |
| gefitinib | increases response to substance | ISO | RGD:734299 | 6480464 | BCL2L11 protein results in increased susceptibility to gefitinib | CTD | PMID:20237869 |
| imatinib | increases response to substance | ISO | RGD:734299 | 6480464 | BCL2L11 protein results in increased susceptibility to imatinib | CTD | PMID:19403302 |
| isoflurane | decreases expression | EXP | | 6480464 | Isoflurane results in decreased expression of BCL2L11 mRNA | CTD | PMID:16978161 |
| isoprenaline | increases expression | ISO | RGD:734300 | 6480464 | Isoproterenol results in increased expression of BCL2L11 protein | CTD | PMID:14996839 |
| lead diacetate | increases expression | ISO | RGD:734300 | 6480464 | lead acetate results in increased expression of BCL2L11 mRNA | CTD | PMID:21829687 |
| lovastatin | multiple interactions | ISO | RGD:734299 | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] | CTD | PMID:18766339 |
| lovastatin | increases expression | ISO | RGD:734299 | 6480464 | Lovastatin results in increased expression of BCL2L11 protein | CTD | PMID:18766339 |
| LY294002 | multiple interactions | ISO | RGD:734299 | 6480464 | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein | CTD | PMID:20856197 |
| LY294002 | multiple interactions | ISO | RGD:734299 | 6480464 | resveratrol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form] | CTD | PMID:21179458 |
| LY294002 | increases expression | ISO | RGD:734299 | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form | CTD | PMID:21179458 |
| medroxyprogesterone acetate | multiple interactions | ISO | RGD:734299 | 6480464 | [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein | CTD | PMID:16709600 |
| mercury atom | decreases expression | ISO | RGD:734299 | 6480464 | Mercury results in decreased expression of BCL2L11 mRNA | CTD | PMID:19937285 |
| mercury(0) | decreases expression | ISO | RGD:734299 | 6480464 | Mercury results in decreased expression of BCL2L11 mRNA | CTD | PMID:19937285 |
| microcystin-LR | increases expression | ISO | RGD:734300 | 6480464 | cyanoginosin LR results in increased expression of BCL2L11 mRNA | CTD | PMID:17654400 |
| monodansylcadaverine | increases expression | ISO | RGD:734299 | 6480464 | monodansylcadaverine results in increased expression of BCL2L11 protein | CTD | PMID:16170020 |
| morphine | increases expression | ISO | RGD:734299 | 6480464 | Morphine results in increased expression of BCL2L11 protein | CTD | PMID:19292871 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:734299 | 6480464 | Acetylcysteine inhibits the reaction [[bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] | CTD | PMID:15173094 |
| N-methyl-N'-nitro-N-nitrosoguanidine | multiple interactions | EXP | | 6480464 | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein; more ... | CTD | PMID:16030430 |
| nickel atom | multiple interactions | ISO | RGD:734299 | 6480464 | trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA] | CTD | PMID:14575637 |
| nickel atom | affects expression | ISO | RGD:734299 | 6480464 | Nickel affects the expression of BCL2L11 mRNA | CTD | PMID:14575637 |
| nickel dichloride | affects expression | EXP | | 6480464 | nickel chloride affects the expression of BCL2L11 mRNA | CTD | PMID:22110744 |
| nickel sulfate | increases expression | ISO | RGD:734299 | 6480464 | nickel sulfate results in increased expression of BCL2L11 mRNA | CTD | PMID:17382205 |
| paclitaxel | affects response to substance | ISO | RGD:734300 | 6480464 | BCL2L11 protein affects the susceptibility to Paclitaxel | CTD | PMID:17652622 |
| paracetamol | multiple interactions | ISO | RGD:734300 | 6480464 | PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA] | CTD | PMID:17585979 |
| paracetamol | increases expression | ISO | RGD:734299 | 6480464 | Acetaminophen results in increased expression of BCL2L11 mRNA | CTD | PMID:21420995 |
| paracetamol | affects expression | ISO | RGD:734300 | 6480464 | Acetaminophen affects the expression of BCL2L11 mRNA | CTD | PMID:17562736 |
| paraquat | decreases expression | ISO | RGD:734299 | 6480464 | Paraquat results in decreased expression of BCL2L11 mRNA | CTD | PMID:18836921 |
| phenobarbital | decreases expression | ISO | RGD:734300 | 6480464 | Phenobarbital results in decreased expression of BCL2L11 mRNA | CTD | PMID:19270015 |
| phenobarbital | affects expression | ISO | RGD:734300 | 6480464 | Phenobarbital affects the expression of BCL2L11 mRNA | CTD | PMID:23091169 |
| pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of BCL2L11 mRNA | CTD | PMID:12832660 |
| raloxifene | increases expression | ISO | RGD:734299 | 6480464 | Raloxifene results in increased expression of BCL2L11 mRNA | CTD | PMID:19429434 |
| rel-(3R,5S)-fluvastatin | multiple interactions | ISO | RGD:734299 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA | CTD | PMID:16996129 |
| resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:17636462 |
| resveratrol | increases expression | ISO | RGD:734300 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:21980390 |
| resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:17636462 PMID:21980390 |
| resveratrol | increases expression | ISO | RGD:734300 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:20026400 PMID:21980390 |
| resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein alternative form | CTD | PMID:21179458 |
| resveratrol | multiple interactions | ISO | RGD:734299 | 6480464 | FOXO1 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form]; more ... | CTD | PMID:21179458 |
| resveratrol | increases response to substance | ISO | RGD:734299 | 6480464 | BCL2L11 protein results in increased susceptibility to resveratrol | CTD | PMID:22245142 |
| resveratrol | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 protein promotes the reaction [resveratrol results in increased activity of BAK1 protein] | CTD | PMID:22245142 |
| romidepsin | multiple interactions | ISO | RGD:734299 | 6480464 | Acetylcysteine inhibits the reaction [[bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] | CTD | PMID:15173094 |
| romidepsin | increases expression | ISO | RGD:734299 | 6480464 | romidepsin results in increased expression of BCL2L11 protein | CTD | PMID:15069698 PMID:18223231 |
| romidepsin | increases expression | ISO | RGD:734299 | 6480464 | romidepsin results in increased expression of BCL2L11 protein | CTD | PMID:18223231 PMID:15069698 |
| selenium atom | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium]; more ... | CTD | PMID:17339365 |
| selenium atom | increases expression | ISO | RGD:734299 | 6480464 | Selenium results in increased expression of BCL2L11 protein | CTD | PMID:17339365 |
| silicon dioxide | increases expression | ISO | RGD:734300 | 6480464 | Silicon Dioxide results in increased expression of BCL2L11 mRNA | CTD | PMID:19073995 |
| sirolimus | multiple interactions | ISO | RGD:734299 | 6480464 | [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of BCL2L11 protein; more ... | CTD | PMID:21092744 |
| sirolimus | decreases expression | ISO | RGD:734300 | 6480464 | Sirolimus results in decreased expression of BCL2L11 protein | CTD | PMID:18097008 |
| sirolimus | increases expression | ISO | RGD:734299 | 6480464 | Sirolimus results in increased expression of BCL2L11 protein | CTD | PMID:21092744 |
| sodium chloride | multiple interactions | EXP | | 6480464 | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein; more ... | CTD | PMID:16030430 |
| succimer | multiple interactions | ISO | RGD:734300 | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of BCL2L11 mRNA | CTD | PMID:21641980 |
| tamoxifen | multiple interactions | ISO | RGD:734299 | 6480464 | Tamoxifen promotes the reaction [methylselenic acid results in increased cleavage of BCL2L11 protein] | CTD | PMID:18790785 |
| taurine | multiple interactions | EXP | | 6480464 | Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein alternative form] | CTD | PMID:20830294 |
| testosterone | increases expression | EXP | | 6480464 | Testosterone deficiency results in increased expression of BCL2L11 protein | CTD | PMID:20850791 |
| tetrachloromethane | increases expression | ISO | RGD:734300 | 6480464 | Carbon Tetrachloride results in increased expression of BCL2L11 protein; more ... | CTD | PMID:17482686 |
| tetrachloromethane | multiple interactions | ISO | RGD:734300 | 6480464 | PLG protein affects the reaction [Carbon Tetrachloride results in increased expression of BCL2L11 protein] | CTD | PMID:17482686 |
| tetrathiomolybdate(2-) | multiple interactions | EXP | | 6480464 | [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein; more ... | CTD | PMID:22276220 |
| trans-resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:17636462 |
| trans-resveratrol | multiple interactions | ISO | RGD:734299 | 6480464 | FOXO1 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form]; more ... | CTD | PMID:21179458 |
| trans-resveratrol | increases expression | ISO | RGD:734300 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:21980390 |
| trans-resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:17636462 PMID:21980390 |
| trans-resveratrol | increases expression | ISO | RGD:734300 | 6480464 | resveratrol results in increased expression of BCL2L11 protein | CTD | PMID:20026400 PMID:21980390 |
| trans-resveratrol | increases expression | ISO | RGD:734299 | 6480464 | resveratrol results in increased expression of BCL2L11 protein alternative form | CTD | PMID:21179458 |
| trans-resveratrol | increases response to substance | ISO | RGD:734299 | 6480464 | BCL2L11 protein results in increased susceptibility to resveratrol | CTD | PMID:22245142 |
| trans-resveratrol | multiple interactions | ISO | RGD:734299 | 6480464 | BCL2L11 protein promotes the reaction [resveratrol results in increased activity of BAK1 protein] | CTD | PMID:22245142 |
| trichostatin A | multiple interactions | ISO | RGD:734299 | 6480464 | trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA] | CTD | PMID:14575637 |
| trimellitic anhydride | increases expression | ISO | RGD:734300 | 6480464 | trimellitic anhydride results in increased expression of BCL2L11 mRNA | CTD | PMID:19042947 |
| valproic acid | affects expression | ISO | RGD:734300 | 6480464 | Valproic Acid affects the expression of BCL2L11 mRNA | CTD | PMID:17963808 |
| zinc atom | increases expression | ISO | RGD:734299 | 6480464 | Zinc results in increased expression of BCL2L11 mRNA | CTD | PMID:19071009 |
| zinc(0) | increases expression | ISO | RGD:734299 | 6480464 | Zinc results in increased expression of BCL2L11 mRNA | CTD | PMID:19071009 |
| zoledronic acid | multiple interactions | ISO | RGD:734299 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA | CTD | PMID:16996129 |